Drugs / Medical Cannabis
Trials 6
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 23 trials | ||||||
| Phase 2 | NCT06490445 | Nov 2024 → May 2026 | diabetic polyneuropathy | Syqe Medical | Completed | No outcome recorded |
| Phase 2 | NCT06605430 | Sep 2024 → Sep 2026 overdue | colorectal cancer, malignant pancreatic neoplasm | HealthPartners Institute | Recruiting | No outcome recorded |
| Phase 2 | NCT06518434 | Apr 2021 → Apr 2027 expected | hepatocellular carcinoma | University Medical Center Groningen | Recruiting | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT03808935 | Jan 2019 → Mar 2020 | epilepsy | The Epilepsy Research Program of the Ontario Brain Institute | Terminated | No outcome recorded |
| Phase not applicable2 trials | ||||||
| — | NCT06217146 | Oct 2022 → Mar 2024 | Alzheimer disease, disruptive behavior disorder | M. H MediCane Ltd. | Terminated | No outcome recorded |
| — | NCT04376437 | Mar → Dec 2022 | chemotherapy-induced neuropathy | HaEmek Medical Center, Israel | Unknown | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 7 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Medical Cannabis | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03808935 ↗ |
| Action | Activate | “Cannabinoids exert many effects through activation of G-protein-coupled cannabinoid receptors in the brain and peripheral tissues.” PMID 12648025 ↗ 2003 |
| Route | Inhaled | “inhalation by using a Portable Metered-Dose Cannabis Inhaler” NCT04376437 ↗ |